The Effect of Combined Treatment with Olanzapine and 
Aripiprazole on Schizophrenia and Analysis of TC, TG, 
and Fasting Plasma Glucose (FPG) Levels

Shuai Gao; Xuejing Li; Xianqiang Zhang; Yuanhui Zhong; Desheng Li; Weiwei Yang

doi:10.70711/pmr.v2i7.7715

The Effect of Combined Treatment with Olanzapine and Aripiprazole on Schizophrenia and Analysis of TC, TG, and Fasting Plasma Glucose (FPG) Levels

Shuai Gao, Xuejing Li, Xianqiang Zhang, Yuanhui Zhong, Desheng Li, Weiwei Yang

Abstract

Objective: To explore the clinical efficacy of combined treatment with olanzapine and aripiprazole in patients with schizophrenia
and evaluate its impact on glucose and lipid metabolism. Methods: A retrospective selection was made of the data of 50 patients with schizophrenia admitted to the hospital from March 2024 to March 2025. The patients were divided into a control group (25 cases) and an observation group (25 cases) based on the difference in treatment methods. The control group received olanzapine monotherapy, while the observation
group received combined treatment with olanzapine and aripiprazole. The clinical efficacy, Positive and Negative Syndrome Scale (PANSS),
fasting plasma glucose (FPG), insulin resistance index (HOMA-IR), triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were compared between the two groups. Results: The total clinical effective
rate of the observation group was higher than that of the control group (P < 0.05). After treatment, the PANSS scores of both groups decreased
compared to before, and the observation group had a relatively lower score (P < 0.05). After treatment, the FPG and HOMA-IR of both groups
improved to varying degrees, and the improvement in the observation group was more significant (P < 0.05). After treatment, the lipid indicators
of both groups improved, and the improvement in the observation group was particularly prominent (P < 0.05). Conclusion: The combined use
of olanzapine and aripiprazole in the treatment of schizophrenia has an excellent overall efficacy, can significantly improve the mental symptoms of patients, and has a regulatory effect on glucose and lipid metabolism.

Keywords

Schizophrenia; Olanzapine; Aripiprazole; Fasting Plasma Glucose; Lipid Indicators

Full Text:

PDF

Included Database

References

[1] Zhang Xiaojuan, Liu Pengfei, Bai Meina, et al. The effect of olanzapine combined with aripiprazole on clinical symptoms and adverse

reactions in patients with schizophrenia [J]. International Journal of Psychiatry, 2025, 52(1): 50-53, 71.

[2] Zheng Dongcui, Kan Bo, Zhu Bai, et al. The effect of aripiprazole combined with olanzapine on glucose and lipid metabolism and endocrine function in patients with schizophrenia [J]. Journal of Clinical and Experimental Medicine, 2024, 23(7): 702-705.

[3] Liu Shunhua, Yuan Xiaofeng, Ye Xueting, et al. The effect of aripiprazole combined with olanzapine on male inpatients with schizophrenia and its influence on metabolic syndrome [J]. Sichuan Mental Health, 2024, 37(3): 226-231.

[4] Ministry of Health Health Statistics Information Center. Application Guidance Manual of International Classification of Diseases (ICD-

10) [M]. Peking Union Medical College Press, 2001.

[5] Wang Jian, Zhao Yong, He Jiangli, et al. The efficacy of aripiprazole and olanzapine in the treatment of first-episode schizophrenia and

their effects on prolactin levels [J]. International Journal of Psychiatry, 2023, 50(4): 655-658, 662.

[6] Jiang Wei, Wang Zhenhua, Ling Yunxiang. The clinical effect of low-dose aripiprazole combined with olanzapine in the treatment of

schizophrenia and its influence on serum prolactin [J]. Chinese Journal of Drugs and Clinics, 2023, 23(3): 155-159.

[7] Chen Caihong, Zhang Weihong, Lin Peiyi. The effect of olanzapine combined with different doses of aripiprazole on glucose and lipid

metabolism in patients with schizophrenia [J]. Guizhou Medical Journal, 2022, 46(7): 1043-1044.

[8] Guo Ting, Wu Yue, Zhou Zhenhe. Comparison of the effects of aripiprazole and olanzapine on effortful cognition, executive and decision-making functions in patients with chronic schizophrenia [J]. Anhui Medicine, 2022, 26(3): 617-621.

[9] Zhang Haixia, Zhang Qi, Zhu Lili, et al. The effect of aripiprazole combined with olanzapine on symptoms and sleep in patients with

schizophrenia [J]. International Journal of Psychiatry, 2022, 49(3): 444-446.

[10] Sun Q, Zou L, Wan A. Effects of Aripiprazole, Olanzapine and Risperidone on Heart Rate Variability in First-Episode Schizophrenia

Patients [J]. Journal of Nanchang University (Medical Sciences), 2022, 62(3): 34-37.

[11] Yan T, Zhang R, Tu L, et al. Effects of Aripiprazole on Serum Retinol Binding Protein 4 in Patients with Weight Gain Induced by Olanzapine [J]. Journal of Mental Health, 2023, 36(5): 472-475.

[12] Yan T, Zhang R, Tu L, et al. Effects of Aripiprazole on Serum Retinol Binding Protein 4 in Patients with Weight Gain Induced by Olanzapine [J]. Journal of Mental Health, 2022, 35(5): 472-475.

[13] Xu H, Zhang M, Cao Y, et al. Network Meta-Analysis of the Effects of Second-Generation Antipsychotic Drugs on Metabolic Syndrome-Related Indicators in Schizophrenia Patients [J]. Chinese Journal of New Drugs, 2022, 31(19): 1952-1961.

DOI: http://dx.doi.org/10.70711/pmr.v2i7.7715

Refbacks

There are currently no refbacks.